A major appeal of exRNA biomarkers is their potential to improve non-invasive diagnosis of MASLD and MASH, compared to conventional tests like alanine aminotransferase (ALT), FIB-4 score or imaging. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.